← Search & browse all drugs

evinacumab

C10AX17

Forms & Strengths

Solution for injection 60 mg/3 mL
Solution for injection 100 mg/5 mL
Solution for injection 150 mg/7.5 mL
Solution for injection 200 mg/10 mL

Adult Dosing

15 mg/kg every 4 weeks
Dose may be adjusted based on LDL-C response

Pediatric Dosing

Safety and efficacy not established in pediatric patients
Use in pediatric patients not recommended

Indications

Homozygous familial hypercholesterolemia
Primary hypercholesterolemia in adults with LDL-C ≥ 130 mg/dL

Mechanism of Action

Angiopoietin-like protein 3 (ANGPTL3) inhibitor
Reduces ANGPTL3-mediated inhibition of lipoprotein lipase
Increases lipoprotein lipase activity
Decreases triglyceride-rich lipoprotein and LDL-C levels

Contraindications

Hypersensitivity to evinacumab or excipients

Adverse Reactions

Injection site reaction
Fatigue
Migraine
Upper respiratory tract infection
Back pain

Drug Interactions

No clinically significant interactions with statins or ezetimibe
No significant effect on warfarin pharmacokinetics

Curated Content: Needs Vetting Before Put to Clinical Use